# Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

> **NCT00876252** · PHASE2 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 400 (actual)

## Conditions studied

- Pneumonia, Ventilator-Associated

## Interventions

- **BIOLOGICAL:** IC43
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00876252
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2012-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876252, "Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00876252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*